The article is devoted to evaluating the effectiveness of transcranial magnetic stimulation in the complex therapy of treatment-resistant depressions complicated by residual organic insufficiency of the central nervous system. For this purpose, a sample of 109 patients with this pathology was randomly divided into a main group (55 people) and a control group (54 people). The patients of the main group received a combination of antidepressants and 12 sessions of transcranial magnetic stimulation according to the iTBS protocol. The patients of the control group received only psychopharmacotherapy with a combination of antidepressants. The patients of both groups were examined at 2 and 4 weeks from the start of treatment, as well as in the catamnesis after 1 month and 6 months after the end of treatment, using BDI, BAI, CGI-S, and CGI–I questionnaires. It has been proved that the complex therapy of treatment-resistant depressions complicated by residual organic insufficiency of the central nervous system with the use of TMS sessions and psychopharmacotherapy is more effective than with isolated psychopharmacotherapy, which was confirmed by a statistically significant more pronounced reduction in the severity of depression and anxiety according to psychometric questionnaires and an improvement of the clinical condition on the CGI–I scale.

No abstract

Affective disorders in patients with Parkinson's disease (PD) are significantly more common than in the general population in people of the same age. It is known that the ef ficacy of antidepressants in PD patients is lower than in patients with a depressive disorder not associated with PD. Therefore, such patients may take high doses of antidepressants, which is accompanied by side effects manifestations and a decrease in quality of life. Transcranial magnetic stimulation (TMS) is a safe treatment for depressive disorder that has been successfully used in PD patients. The article presents a comparison of the effectiveness of complex therapy with TMS and SSRIs with SSRI monotherapy for the treatment of depressive disorder in PD patient.

This article discusses the relationship of three global topics, each of which is of particular interest in the scientific community: transcranial magnetic stimulation as a treatment method, treatment-resistant depression, and residual-organic insufficiency of the central nervous system. Depression has become one of the most common diseases in the world, affecting more than 264 million people. According to various clinical data, drug therapy is effective in about 70 % of cases. In the remaining 30 %, there is no efficiency, or it turns out to be incomplete. These conditions can be comorbid with a variety of exogenous organic symptoms. Up to 30 % of patients seeking medical help in connection with neurotic disorders have signs of residual-organic insufficiency. The treatment of these conditions requires the search for methods to resolve them. One of these methods is transcranial magnetic stimulation. It is a non-invasive and well-tolerated treatment for depression, with proven clinical efficacy.